Alector (ALEC) Shares Outstanding (2018 - 2026)
Alector's (ALEC) quarterly Shares Outstanding (Entity) came in at $111.7 million in Q2 2026, up 10.32% year-over-year from $101.2 million in Q2 2025, and up 0.57% quarter-over-quarter from $111.0 million in Q1 2026.
Analysis
Alector (ALEC) Shares Outstanding (2018 - 2026) Analysis & Trends
Alector (ALEC) has reported Shares Outstanding (Entity) for 9 consecutive years, with $111.7 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Shares Outstanding (Entity) rose 10.32% year-over-year to $111.7 million in Q2 2026; TTM through Jun 2026 was $111.7 million, a 10.32% increase from a year earlier, with the FY2025 full-year figure at $110.4 million, up 11.38% from the prior year.
- Shares Outstanding (Entity) was $111.7 million for Q2 2026 at Alector, up from $111.0 million in the prior quarter.
- Over five years, Shares Outstanding (Entity) peaked at $111.7 million in Q2 2026 and troughed at $82.0 million in Q1 2022.
- A 5-year average of $94.3 million and a median of $96.9 million in 2024 frame the typical range for Shares Outstanding (Entity).
- Across the five-year window, Shares Outstanding (Entity) advanced 1.11% in 2022 and climbed 16.74% in 2024, its largest moves.
- Over 5 years, Shares Outstanding (Entity) stood at $82.9 million in 2022, then climbed by 2.39% to $84.9 million in 2023, then grew by 16.74% to $99.1 million in 2024, then gained by 11.38% to $110.4 million in 2025, then rose by 1.17% to $111.7 million in 2026.
- The last three Shares Outstanding (Entity) figures came in at $111.7 million (Q2 2026), $111.0 million (Q1 2026), and $110.4 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 540.00 Mn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 1.24 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 253.70 Mn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 102.80 Mn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 61.30 Mn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 398.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 133.61 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 147.70 Mn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Alector | 274.68 Mn | 101.88 Mn | - | 111.22 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 111.22 Mn |
| Mar 31, 2026 | 110.59 Mn |
| Dec 31, 2025 | 103.00 Mn |
| Sep 30, 2025 | 102.60 Mn |
| Jun 30, 2025 | 100.37 Mn |
| Mar 31, 2025 | 99.40 Mn |
| Dec 31, 2024 | 96.59 Mn |
| Sep 30, 2024 | 97.52 Mn |
| Jun 30, 2024 | 96.67 Mn |
| Mar 31, 2024 | 93.81 Mn |
| Dec 31, 2023 | 83.73 Mn |
| Sep 30, 2023 | 83.93 Mn |
| Jun 30, 2023 | 83.50 Mn |
| Mar 31, 2023 | 83.10 Mn |
| Dec 31, 2022 | 82.47 Mn |
| Sep 30, 2022 | 82.60 Mn |
| Jun 30, 2022 | 82.39 Mn |
| Mar 31, 2022 | 82.10 Mn |
| Dec 31, 2021 | 80.42 Mn |
| Sep 30, 2021 | 80.96 Mn |